Association of Lupus Anticoagulant status with Disease Course in SARS-CoV-2 (COVID-19) Infection.
Clin Appl Thromb Hemost
; 28: 10760296221127276, 2022.
Article
in English
| MEDLINE | ID: covidwho-2053691
ABSTRACT
Background:
We investigated the importance of lupus anticoagulant (LA) in patients with SARS-CoV-2.Methods:
Medical records of 41 SARS-CoV-2 infected patients were reviewed. Patients were classified into two groups according to the frequency of positive LA testresults:
"LA (-)" and "LA (+) ≥1" (LA positive at least once). Statistical analysis was performed to determine the association between LA presence and change in LA test results and disease course according to both hospital days (HD) and days after diagnosis (DD).Results:
The prevalence of LA was 51.2%. Averagely, the first change in LA test result occurred during DD 12-13 and between HD 9-10. The second change occurred on DD 15-16 and HD 13-14. The presence of LA was associated with severe disease (P = .004) but was not associated with thrombotic complications or mortality. The change of results from negative to positive or vice versa or the frequency of the changes was not associated with disease severity, thrombotic complications, or mortality.Conclusions:
LA positivity can be regarded as one of the findings suggesting more serious SARS-CoV-2 infection.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Thrombosis
/
Antiphospholipid Syndrome
/
COVID-19
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Clin Appl Thromb Hemost
Journal subject:
Vascular Diseases
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS